News

Accelerating Database Modernization with Cockroach Labs and AWS

Accelerating Database Modernization with Cockroach Labs and AWS

Collaboration Between Cockroach Labs and AWS

Cockroach Labs, a leader in cloud-native distributed SQL databases, is joining forces with Amazon Web Services (AWS) to revolutionize how businesses modernize their Windows-based applications and databases. By leveraging generative AI-powered transformation capabilities, this collaboration aims to rejuvenate outdated .NET applications that rely on traditional, monolithic legacy databases.

The Need for Modernization

As companies increasingly focus on cost-efficiency and superior infrastructure, the modernization of IT systems has become paramount. Many enterprises struggle to transition their .NET applications due to dependencies on outdated legacy databases, which are not designed to take full advantage of cloud benefits. These older systems often lack scalability, incur high maintenance costs, and fail to provide multi-region support, thereby limiting business growth and resource optimization.

Innovative Solutions with AI

Allen Terleto, VP Global Partners and Ecosystem at Cockroach Labs, expressed enthusiasm about the collaboration, stating, "We're excited to deepen our relationship with AWS to streamline and reduce the risks associated with .NET application modernization. Our partnership aims to empower developers by providing the necessary tools to create scalable, resilient applications that take full advantage of AWS's infrastructure. CockroachDB's capabilities will facilitate seamless database migration and integrate well with legacy RDBMS features, allowing developers to harness cloud-native benefits effectively."

Customer Success Stories

Customers of Cockroach Labs, such as Route, illustrate the effectiveness of their solutions. Route recognized the importance of implementing a distributed cloud database to support their critical operations, which included managing over 1 billion orders. By migrating to CockroachDB on AWS, Route ensured continuous data availability and improved system resilience.

Embracing Cloud-Native Architecture

The partnership between Cockroach Labs and AWS provides enterprises with a comprehensive solution to modernize legacy applications fully. Through success stories and robust tools like Amazon Q Developer, organizations can accelerate their modernization journeys and transition to modern, always-on cloud-native applications, bolstered by CockroachDB's inherent resilience and performance capabilities.

Why Choose CockroachDB?

CockroachDB is designed to scale effortlessly while providing robust performance, making it perfect for any mission-critical workload. By modernizing with CockroachDB on AWS, businesses can ensure they are equipped to handle increasing data demands while lowering operational costs and enhancing their responsiveness to market changes.

About Cockroach Labs

Cockroach Labs operates at the cutting edge of database technology and is committed to delivering scalable and resilient solutions for critical business needs. Their innovative distributed SQL database, CockroachDB, has been instrumental for clients such as Bose, Form3, and Shipt, helping them modernize their data management strategies and stay competitive in fast-paced industries. The mission of Cockroach Labs is clear: to provide systems that scale seamlessly, even when faced with the challenges of high demand and complex data environments.

Frequently Asked Questions

What is the primary focus of the collaboration between Cockroach Labs and AWS?

The collaboration aims to modernize Windows-based applications dependent on monolithic legacy databases using AI-powered transformation tools.

How does CockroachDB facilitate database migration?

CockroachDB offers seamless compatibility with legacy RDBMS features and enhances scalability, making it easier for enterprises to migrate their data with minimal disruption.

Who are some clients that have benefited from CockroachDB?

Notable clients include Route, Bose, Form3, and Shipt, showcasing CockroachDB's ability to meet the demands of mission-critical workloads.

What are the advantages of using cloud-native architecture?

Cloud-native architecture promotes better scalability, often reducing costs and improving performance through distributed systems designed for modern data requirements.

How can companies get started with CockroachDB on AWS?

Businesses interested in trying CockroachDB can visit the Cockroach Labs website to explore the offerings and begin their modernization journey.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 6

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 3

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 6

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 7

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 21

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 7

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 3

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 6

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 6

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading

Top 5 Most Recently Viewed Articles

Investing Insights: Man Group PLC's Position in Spectris plc

Updated Category News Views 315

Understanding Man Group PLC's Investment Position Man Group PLC, a primary player in investment management, recently announced its public interests regarding relevant securities in Spectris plc. This disclosure highlights its strategic investment and positions in the market. Key Information Disclosure As per regulatory requirements, Man Group PLC has provided essential...

Continue Reading
Coca Cola Surpasses Expectations Amidst Market Challenges

Updated Category News Views 357

Coca Cola Surpasses Expectations Amidst Market Challenges On a recent earnings announcement, The Coca Cola Company (NYSE: KO) exceeded Wall Street predictions, showcasing a resilient strategy to enhance revenue and earnings despite shifting consumer preferences. While demand for beverages has softened, Coca Cola's ability to raise prices proved beneficial, even as...

Continue Reading
Joget Enhances Application Development Using AI and Security

Updated Category News Views 86

Transforming Application Development with Joget AI The innovative Vibe Composition approach by Joget empowers enterprises to craft robust applications by utilizing trusted, composable components rather than traditional raw coding methods. This modern take on application development is encapsulated within the Joget AI Designer, making the process both efficient and secure....

Continue Reading
Gimme Credit Unveils Innovative Platform to Enhance Global Research

Updated Category News Views 215

Introducing Gimme Credit's New Client Platform Gimme Credit, a prominent independent provider of credit research and data, has recently launched a cutting-edge delivery platform. This initiative marks a significant step in the company's global expansion and innovation efforts. An Era of Growth and Technological Innovation The new platform utilizes a cloud-based...

Continue Reading
Comprehensive Overview of SCOR's Share and Voting Rights Data

Updated Category News Views 36

Understanding SCOR's Share Capital and Voting Rights In today's competitive landscape, it is crucial for companies to maintain transparency regarding their operations and shareholder information. SCOR, a notable player in the global reinsurance market, has recently provided an insightful declaration concerning its share capital and voting rights. This information...

Continue Reading